Alpine Immune Sciences initiated with a Buy at Berenberg

Berenberg initiated coverage of Alpine Immune Sciences with a Buy rating and $18 price target. Over the next year, multiple catalysts should drive the stock price higher, while over the long term, Alpine will likely be in a “prime position to run low-risk trials and quickly enter markets that have strong revenue potential,” the analyst tells investors in a research note.